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Parkinson’s disease (PD) is a progressive neurodegenerative disorder causing movement
disabilities and several non-motor symptoms in afflicted patients. Recent studies in
animal models of PD and analyses of brain specimen from PD patients revealed an
increase in the level and activity of the non-receptor tyrosine kinase Abelson (c-Abl) in
dopaminergic neurons with phosphorylation of protein substrates, such as α-synuclein
and the E3 ubiquitin ligase, Parkin. Most significantly inhibition of c-Abl kinase activity
by small molecular compounds used in the clinic to treat human leukemia have shown
promising neuroprotective effects in cell and animal models of PD. This has raised hope
that similar beneficial outcome may also be observed in the treatment of PD patients
by using c-Abl inhibitors. Here we highlight the background for the current optimism,
reviewing c-Abl and its relationship to pathophysiological pathways prevailing in PD,
as well as discussing issues related to the pharmacology and safety of current c-Abl
inhibitors. Clearly more rigorously controlled and well-designed trials are needed before
the c-Abl inhibitors can be used in the neuroclinic to possibly benefit an increasing
number of PD patients.
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Age is a major risk factor for Parkinson’s disease (PD), but the precise molecular mechanisms
underlying the disease are not fully understood. Recent advances in genetics and pathophysiology
of PD have increased our understanding about the fundamental processes contributing to disease
pathogenesis but in the majority of cases the precise etiology is unknown. However, evidence
suggests that protein aggregation, mitochondrial dysfunctions, ER stress, neuroinflammation and
reduced growth factor levels contribute to neurodegeneration and play key roles in PD (Gupta
et al., 2008; Fahn, 2010; Mullin and Schapira, 2015). Studies of gene mutations causing familial PD
have identified proteins such as α-synuclein and the E3 ubiquitin ligase, Parkin that are important
Abbreviations: ALL, acute lymphoblastic leukemia; BBB, blood-brain barrier; BCR, Breakpoint cluster region protein;
c-Abl, cellular homolog of the Abelson murine leukemia virus oncogene; Cdk5, cyclin-dependent kinase 5; CML,
chronic myeloid leukemia; Fyn, Src family tyrosine kinase; Lyn, Src family tyrosine kinase; MPTP, N-methyl-4-
phenyl-1, 2, 3, 6-tetrahydroyridine; Paris, PARkin Interacting Substrate; PD, Parkinson’s disease; PGC-1α, Peroxisome
proliferator-activated receptor-γ coactivator-1α.
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also in the more common sporadic forms of PD (Singleton
et al., 2003; Dawson and Dawson, 2011). One hallmark of
PD is the aggregation of α-synuclein in the complex with
other proteins in so called Lewy bodies particularly within
dopaminergic neurons in the midbrain, though the precise role
of this protein accumulation is currently unclear (Spillantini
et al., 1997; Winslow and Rubinsztein, 2011). Defects in
protein handling involving dysfunctional autophagy, and the
ubiquitin-proteasome system as well as ER stress and changes
in posttranslational modifications of proteins with altered cell
signaling cascades can contribute to the process of protein
accumulation and degeneration of dopamine neurons (Lindholm
et al., 2006; Winslow and Rubinsztein, 2011; Klionsky et al.,
2016).
In PD, the levels of the neurotransmitter dopamine decrease
in the brain caused by the degeneration and final loss
of dopamine neurons in substantia nigra. Many symptoms
especially those related to altered movement patterns in PD can
be treated with L-Dopa, a drug restoring the levels of dopamine.
However, L-Dopa does not halt the progressive decline in
dopamine neurons, and may in the long term produce severe
dyskinesia. It is thus of utmost importance to find therapies
to counteract the neurodegeneration and restore the neuronal
circuits in the brain of PD patients. Previous research on
pathophysiological processes in PD has also helped to identify
novel and promising targets for neuroprotection (Brundin et al.,
2015; Kalia et al., 2015; Lindholm et al., 2016). Unfortunately
many novel molecules and trophic factors showing promising
data in preclinical experiments and animal models of PD have
failed to recapitulate these in more rigorous clinical trials (Kalia
et al., 2015; Lindholm et al., 2016).
It is therefore gratifying to note that older drugs previously
used for treatment of other disorders may have potentially
beneficial effects in neurodegenerative diseases including PD
(Patrone et al., 2014). Among these are the thiazolidine
drugs used in the treatment of type-2 diabetes that act
via the nuclear peroxisome proliferator-activated receptor-γ
co-activator -1α (PGC-1α), as well as the more novel compounds
like exenatide stimulating glucagon-like peptide receptor (Aviles-
Olmos et al., 2014; Patrone et al., 2014). Preclinical studies
of these compounds have revealed significant neuroprotective
effects in animal models of PD and in other brain disorders.
The recent additions to this list of promising disease-modifying
compounds in PD include small molecule inhibitors targeting
the activity of the c-Abl tyrosine kinase (Hebron et al., 2013;
Imam et al., 2013; Karuppagounder et al., 2014; Tanabe et al.,
2014).
WHAT IS c-Abl?
c-Abl (ABL1) is the cellular homolog of the Abelson murine
leukemia virus oncogene and belongs to the Abl family of
tyrosine kinase present in the cytoplasm and nucleus of the cell.
c-Abl is expressed inmost cells and is part of an intricate network
of protein interactions and phosphorylation events in the cell
(Hantschel and Superti-Furga, 2004). Thus c-Abl is involved
in a variety of physiological functions including the regulation
of cell growth and motility, cytoskeleton dynamics, receptor
endocytosis, DNA repair, cell survival and autophagy (Hantschel
and Superti-Furga, 2004). c-Abl is normally present in an
inactive form in the cell and its activity is tightly regulated by
intramolecular bonds, as well as by binding to protein complexes,
and linkage to membranes via an aminoterminal myristoyl group
c-Abl is activated following auto-phosphorylation and by the
action of other kinases including Lyn and Fyn that are Src-family
kinases (Figure 1). c-Abl is also activated by DNA damage and
during cell stress involving an increased production of reactive
oxidative species that ultimately can cause cell degeneration
(Hantschel and Superti-Furga, 2004). c-Abl influences several
cell processes acting in concert with other kinases and the key
protein targets of c-Abl may vary in different cells. The consensus
sequence for target phosphorylation by c-Abl is also rather
flexible (see, www.kinasenet.ca), so that novel protein targets
for the kinase should be experimentally verified under actual
physiological conditions.
c-Abl has been previously studied in the context of human
cancers, and mutations in the protein can lead to an enhanced
FIGURE 1 | The role of c-Abl in pathophysiological events in
Parkinson’s disease (PD). Schematic view of the structure and action of
c-Abl in neurons. c-Abl contains the protein kinase region and the SH2 and
SH3 domains. The activity of the protein is tightly regulated in cells by
intramolecular and other interactions and by the Src family kinases Lyn and
Fyn. In addition, increased oxidative stress involving mitochondria can activate
c-Abl leading to subsequent phosphorylation of downstream targets. In the
neurons α-synuclein form intracellular aggregates called Lewy bodies and this
process is aggravated after phosphorylation by c-Abl. Parkin is an ubiquitin
ligase that regulates the mitochondrial biogenesis via the PARkin Interacting
Substrate (Paris) and the transcriptional coactivator Peroxisome
proliferator-activated receptor-γ coactivator-1α (PGC1α) Parkin also controls
mitochondrial dynamics and mitophagy. Phosphorylation by c-Abl inactivates
Parkin leading to mitochondrial alterations and an increased oxidative stress.
This may cause further activation of c-Abl producing a vicious cycle in the
neuron with an enhanced cell degeneration to follow. c-Abl inhibitors may
potentially hinder this cascade by reducing the amount of α-synuclein
aggregates and by restoring the functions of Parkin and of other substrates.
Some of the c-Abl inhibitors are known to block also the Src family kinases
and may thus theoretically be more neuroprotective. A challenge for the c-Abl
inhibitors is that these drugs may not effectively pass the blood-brain barrier
(BBB) possibly limiting their use in PD and other brain disorders.
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protein kinase activity with an increased cell proliferation
(Hantschel and Superti-Furga, 2004). In chronic myeloid
leukemia (CML) there is a chimeric Breakpoint cluster region
protein (BCR)-ABL1 fusion gene present in cells caused by the
translocation between chromosomes 22 (BCR) and 9 (ABL1)
(9;22; q34;q11) producing a fusion gene, encoding a highly active
kinase (Hantschel and Superti-Furga, 2004). The BCR-ABL1
fusion is part of the criteria of the CML diagnosis, but it
is also found in about one-third of adult patients with acute
lymphoblastic leukemia (ALL) and in about 10% ALL children.
It is thought that the differentiation of myeloid precursor cells is
particularly inhibited by the activity of BCR-ABL1 protein, but
other cellular processes are also involved (Quintás-Cardama and
Cortes, 2009).
In contrast to tumor cells, the activity of c-Abl in post-mitotic
neurons is linked to the regulation of the cytoskeleton, to neurite
outgrowth, to neuronal plasticity and to the control of cell stress
(Schlatterer et al., 2011). Data from animal models have shown
that c-Abl is activated in several brain disorders characterized
by an increased oxidative stress, including PD (Schlatterer
et al., 2011). c-Abl was also found to be activated (more
phosphorylated) in brain specimen from PD patients suggesting
a pathophysiological role of c-Abl in the disease (Ko et al.,
2010; Imam et al., 2011; Brahmachari et al., 2016). In support
of this, conditional gene deletion of Abl in the mouse brain
protected dopaminergic neurons in the N-methyl-4-phenyl-
1,2,3,6-tetrahydroyridine (MPTP) neurotoxin model of PD (Ko
et al., 2010). In addition, tyrosine kinase inhibitors against
c-Abl are neuroprotective and can modulate phosphorylation of
specific protein targets in the brain (see below).
INHIBITORS AGAINST c-Abl
Given the importance of BCR-ABL in tumors, specific inhibitors
against the Abl kinase have been searched for the treatment of
blood cancer. Imatinib (STI571, Gleevec/Glivec) was the first
c-Abl tyrosine kinase inhibitor identified and has been used in
the treatment of CML now for several years (Capdeville et al.,
2002; Heffron, 2016). While imatinib generally is well tolerated,
resistance occur in a portion of CML patients over time, and
indicative of the essential driver role of BCR-ABL1 in CML.
Resistance is most commonly mediated by mutations in the
BCR-ABL1 kinase domain that render the kinase insensitive to
imatinib. For this reason, c-Abl inhibitors that are also active
against the most common imatinib resistance mutations have
been designed that can be used in cases when imatinib resistance
occur (Musumeci et al., 2012; Heffron, 2016).
A list of selected c-Abl inhibitors is presented in Table 1
(Heffron, 2016). The presence of a blood-brain barrier (BBB)
effectively hinders most drugs to reach the brain and there
are also active efflux mechanisms further reducing the drug
concentration in the tissue (Heffron, 2016). For treatment of
brain tumors in leukemia, dasatinib (Das et al., 2006) was shown
to penetrate the BBB (Porkka et al., 2008), whereas imanitib
and ponatinib (Huang et al., 2010) do so to a limited extent
(Abid and De Mel, 2016; Heffron, 2016). Regarding nilotinib
and bosutinib (Remsing Rix et al., 2009) recent studies in
animal models of Alzheimer’s disease have shown that these
drugs show a partial BBB penetrance (Lonskaya et al., 2015). It
should be remembered that the state of the BBB may change in
animal models of brain disease not reflecting the real situation
in human patients. Moreover, the optimal concentrations of
drug required to treat neurodegenerative diseases are largely
unknown.
Abl inhibitor therapy in CML is typically handled as a
chronic treatment with patients receiving the drugs for years
to decades. The Abl inhibitors do therefore have to be well
tolerated (Pinilla-Ibarz et al., 2015), arguing for that they could
also be used in continuous treatment of PD with the caution
that different dosing could be needed, hence causing new
adverse effects. Intermittent dosing of Abl inhibitors works
well for treatment of CML (Shah et al., 2008) but it is
possible that more constant serum concentrations will be needed
to produce an effect in neurodegenerative disorders. Issues
related to pharmacodynamics and safety profile of the c-Abl
inhibitors in neurodegenerative treatment deserve particular
attention before a clinical use of the drugs in PD can be
considered.
NILOTINIB AND PD
Nilotinib (AMN107, Tasigna) is a second-generation c-Abl
tyrosine kinase inhibitor that is used in CML in a daily dose of
300 mg to over 1000 mg per patient (Weisberg et al., 2006). The
drug is relatively safe and tolerated but in some patients heart
complications have been associated with the use of nilotinib, and
therefore a black box warning has been given to the drug by the
USA Food and Drug Administration.
As discussed above, preclinical studies show that nilotinib
penetrates into brain tissue and was neuroprotective in two
TABLE 1 | Some properties of current c-Abl inhibitors.
Compound IC50 for c-Abl (nM) in cells Dosage (mg/day) Brain penetration Safety tolerability
Imatinib (Gleevec/Glivec) 100−200 400−600 Poor Good
Nilotinib (Tasigna) 5−10 400−600 Moderate Good∗
Dasatinib (Sprycel) 0.25−0.5 100−180 Moderate Good
Bosutinib (Bosulif) 10−20 500−600 Moderate Good
Ponatinib (Iclusig) 0.25−0.5 15−45 Limited Moderate∗∗
Radotinib∗∗∗ (Supect) 20−40 600−800 Poor Good
∗Black label warning for possible cardiac side effects. ∗∗Black label warning for possible cardiac or liver side effects. ∗∗∗Only approved in South Korea.
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animal models of PD; the MPTP neurotoxin model, and the
one induced by lentiviral overexpression of α-synuclein in the
midbrain (Hebron et al., 2013; Karuppagounder et al., 2014;
Tanabe et al., 2014). Notably the drug improved motor behavior
in these mice, consistent with a beneficial effect on neuronal
circuity involved in movement control. Nilotinib also increased
concentrations of dopamine and its metabolites, homovalinic
acid and 3,4-dihydroxyphenylacetic acid, in brains of MPTP
treated animals (Hebron et al., 2013; Karuppagounder et al.,
2014). It remains to be studied whether nilotinib may also
have restorative and regenerative functions for dopaminergic
neurons and using animal models that resemble more closely
the progressive nature and ageing aspects of PD in human
patients.
A recent clinical study showed that nilotinib reduced
the relative level of phosphorylated (active) c-Abl in the
cerebrospinal fluid of treated PD patients (Pagan et al., 2016).
In search for biochemical correlates for the cytoprotective
effect of nilotinb in brain, mainly two proteins have been in
focus (see Figure 1). Parkin is mutated in autosomal recessive
parkinsonism but it also plays a role in the more common
sporadic PD by affecting ubiquitination of protein targets
(Dawson and Dawson, 2011). Among substrates for Parkin
the protein, PARkin Interacting Substrate (Paris) inhibits the
nuclear coactivator PGC-1α that in turn regulates mitochondrial
biogenesis and functions (Shin et al., 2011). Inactivation of,
or mutations in Parkin increases levels of Paris and reduce
PGC-1α that may lead to mitochondrial dysfunctions and
ultimately to neuronal loss (Shin et al., 2011). In contrast
expression of Parkin or PGC-1α can restore these functions and
counteract the neurodegeneration (Shin et al., 2011; Mudò et al.,
2012). It was subsequently shown that c-Abl phosphorylates
Parkin reducing its neuroprotective ability, whilst treatment with
nilotinib increased Parkin activity (Ko et al., 2010; Dawson and
Dawson, 2011; Imam et al., 2011). In these studies, postmortem
brain samples from PD patients showed an increase in c-Abl
activity along with higher level of Parkin phosphorylation.
In PD, α-synuclein aggregates to form insoluble fibrils
in pathological conditions characterized by Lewy bodies.
α-synuclein is degraded mainly via autophagy including
chaperon-mediated autophagy (Cuervo et al., 2004), and
overexpression of andmodifications/mutations in α-synuclein in
turn, can influence autophagy (Winslow and Rubinsztein, 2011;
Klionsky et al., 2016). Recently it was shown that α-synuclein
is phosphorylated by c-Abl at the tyrosine residue 39 that
negatively regulates its clearance from the cell (Hebron et al.,
2013; Mahul-Mellier et al., 2014; Brahmachari et al., 2016). In
contrast, nilotinib enhanced α-synuclein degradation in cultured
cells and in animal models of PD. Along with this, c-Abl
gene deleted mice have a reduced α-synuclein aggregation and
toxicity (Brahmachari et al., 2016). The link between c-Abl
and α-synuclein seems reciprocal as the overexpression of
α-synuclein can increase c-Abl activity and thereby compromise
autophagy (Hebron et al., 2013).
In Figure 1 we schematically summarize the actions of
c-Abl and its inhibition in the regulation of cell viability in
dopaminergic neurons and the involvement of the protein
targets, α-synuclein and Parkin (Figure 1). In nilotinib-treated
neurons, Parkin and α-synuclein may reinforce each others
actions thereby contributing to a positive effect of the drug
against cell degeneration. One additional target for c-Abl
deserving to be mentioned here is the cyclin-dependent kinase
5 (Cdk5) that is highly expressed in brain neurons and shown to
be activated in neurodegenerative diseases including PD (Smith
et al., 2003; Wen et al., 2014). Cdk5 has several targets in
neurons and influences synaptic plasticity and cell death. Cdk5 is
phosphorylated by glutamate during excitotoxicity (Putkonen
et al., 2011) and by c-Abl during oxidative stress in animal model
of PD (Yamamura et al., 2013). This suggests an important link
between active c-Abl and Cdk5 in the regulation of neuronal
signaling and viability that warrants further studies.
It is important to note that the actual dose of nilotinib
and other c-Abl inhibitors required to achieve an
optimal neuroprotection in PD is currently not known.
Moreover, α-synuclein accumulates also in other forms of
α-synucleinopathies (Spillantini and Goedert, 2016), and in
Dementia with Lewy bodies (DLB). It remains to be studied
whether and to what extent c-Abl is altered in these disorders
and whether an inhibition of c-Abl may offer novel strategies for
treatment.
Recently nilotinib was employed in an open-labeled trial to
treat 12 patients afflicted by either PD or DLB (Pagan et al.,
2016). Since the study lacked proper controls the results are
preliminary and should be treated with caution. The data showed
that administration of nilotinib in a daily dose of 150 mg or
300 mg, lower than the amounts used in blood cancer therapies,
was rather safe and the drug was well tolerated by the patients.
Regarding the clinical outcome, there was also a possible effect on
motor behavior and on cognition of treated patients but the small
group size and the possibility for placebo effects are confounding
factors hindering definitive conclusions.
CONCLUSION
In summary, the recent preclinical data on the protective role
of c-Abl inhibitors in models of PD raised hopes for the
application of these compounds also in the clinics (Wyse et al.,
2016). The recent small open-label drug trial using nilotinib
paved the way in this direction but the results obtained are
so far preliminary (Pagan et al., 2016). In this regard more
carefully designed and well-controlled trials with PD patients
are required to arrive at a conclusion regarding the potential
benefits of c-Abl inhibitors in the treatment of PD. In particular,
studies of the actual doses of nilotinib and of other c-Abl
inhibitors required to achieve an optimal neuroprotection in
PD are warranted to get statistic significance for the effects
observed.
It is to be remembered that the penetration through the
blood brain barrier varies between the different c-Abl inhibitors
and this may also change during the course of the disease. In
this regard the potential use of other delivery routes for these
drugs may be considered, such as the intranasal application of
the drug that is yet to be analyzed. However, in all planned
treatments, issues related to adverse reactions and side effects
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of the c-Abl inhibitors have to be rigorously analyzed since a
long-term treatment with these drugs is foreseen in the case of
neurodegenerative diseases, such as PD.
We also think that before starting phase 2 clinical trials using
c-Abl inhibitors, it is important to conduct experiments on
non-human primate models of PD. Further it should be studied
whether the use of c-Abl inhibitors in PD may help to treat
non-motor symptoms in PD, such as loss of smell, constipation,
sleep disorders, depression and cognitive impairments. In PD
these symptoms derive from changes in enteric and olfactory
dopamine neurons and in neuronal circuits in the brain other
than the dopaminergic nigrostriatal network involved in motor
control. The non-motor symptoms are equally disabling for the
patients and as such require more studies using different drugs
and compounds.
One lesson learned from the recent study of the thiazolidine
drug pioglitazione was that despite promising preclinical data
no significant neuroprotection by the drug was observed in a
larger cohort of PD patients (see study, NINDS Exploratory
Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators
(2015)). Future studies will showwhether nilotinib or other c-Abl
inhibitors can meet the current high expectations, and hopefully
reveal disease-modifying actions in PD for the benefit of an
increasing number of afflicted patients.
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